An eye-opening study carried out at the US Food and Drug Administration’s (FDA) laboratory has uncovered alarmingly high levels of DNA contamination in Pfizer’s mRNA Covid-19 vaccine. The research, conducted at the FDA’s White Oak Campus in Maryland, revealed that residual DNA levels exceeded safety limits by 6 to 470 times.
The study, led by student researchers under the guidance of FDA scientists, analyzed vaccine vials obtained from BEI Resources, a trusted supplier associated with the National Institute of Allergy and Infectious Diseases (NIAID), previously led by Anthony Fauci.
Published in the Journal of High School Science, the peer-reviewed study challenges previous dismissals by regulatory bodies regarding concerns about excessive DNA contamination. Despite the significant findings, the FDA has yet to issue a public alert, recall affected batches, or clarify how vials surpassing safety standards made it to the market.
The researchers utilized two primary analytical methods – NanoDrop Analysis and Qubit Analysis – to confirm the presence of DNA contamination above permissible thresholds. These results corroborate earlier reports from independent laboratories in the United States, Canada, Australia, Germany, and France.
Kevin McKernan, a former director of the Human Genome Project, criticized the FDA for lack of transparency, emphasizing the significance of the findings and the need for public scrutiny. He highlighted potential cancer-causing mechanisms of DNA contamination in the vaccines, raising concerns about the long-term risks associated with repeated exposure.
Regulatory oversight has come under scrutiny, with Professor Nikolai Petrovsky describing the findings as a “smoking gun” that the FDA was aware of. He commended the student researchers for uncovering crucial data that regulators failed to address, emphasizing the need for regulatory bodies to ensure the safety of vaccine products.
The confirmation of DNA contamination in mRNA vaccines poses challenges for manufacturers and regulators, requiring a reassessment of manufacturing processes to address the issue. Prof. Petrovsky suggested that regulators should mandate manufacturers to demonstrate the safety of plasmid DNA levels in vaccines to restore public confidence in oversight.
As the pressure mounts on regulators to act decisively, transparency and accountability are essential to alleviate public skepticism. Both US and Australian drug regulators have been contacted for comments on the matter.
This rewritten article highlights the critical findings of the study while emphasizing the need for regulatory action and transparency in addressing DNA contamination in Covid-19 vaccines.